Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair (ATOMIC)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517269-18-00

Acronym

A021502

Enrollment

Registered

2024-09-18

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stage III colon adenocarcinoma with deficient MMR

Brief summary

Disease-free survival (DFS), defined as the time from randomization to first documentation of disease recurrence (primary tumor relapse) or death.

Interventions

DRUGFLUOROURACIL

DRUGTecentriq 1 200 mg concentrate for solution for infusion

DRUGCALCIUM FOLINATE PENTAHYDRATE

DRUGOXALIPLATIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Disease-free survival (DFS), defined as the time from randomization to first documentation of disease recurrence (primary tumor relapse) or death.	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026